Abstract | OBJECTIVES: METHODS: RESULTS:
Sertraline was prescribed at a median daily dose of 2.2 mg · kg · day. After 3 months, pruritus improved in 14 out of 20 treated patients, and the median itching score decreased significantly from 8/10 (5-10) to 5/10 (2-10). Likewise, skin scratch marks and sleep quality improved in 9 of these 14 patients. Nonsevere adverse events were reported in 6 children, leading to treatment discontinuation in 3. CONCLUSION: Our data suggest that sertraline may constitute a useful drug in the management of refractory cholestatic pruritus in children.
|
Authors | Alice Thébaut, Dalila Habes, Frédéric Gottrand, Christine Rivet, Joseph Cohen, Dominique Debray, Emmanuel Jacquemin, Emmanuel Gonzales |
Journal | Journal of pediatric gastroenterology and nutrition
(J Pediatr Gastroenterol Nutr)
Vol. 64
Issue 3
Pg. 431-435
(03 2017)
ISSN: 1536-4801 [Electronic] United States |
PMID | 27557426
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Serotonin Uptake Inhibitors
- Sertraline
|
Topics |
- Adolescent
- Alagille Syndrome
(complications)
- Child
- Child, Preschool
- Cholestasis, Intrahepatic
(complications)
- Chronic Disease
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Infant
- Male
- Prospective Studies
- Pruritus
(drug therapy, etiology)
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Sertraline
(therapeutic use)
- Treatment Outcome
|